|
BioDelivery Sciences International |
|
|
801 Corporate Center Drive, Suite 210
Raleigh, NC 27607 USA
phone:(919) 582-9050
fax:919-582-9051
|
|
| Symbol |
BDSI |
| Exchange |
NASDAQ |
| Founded |
1997 |
| Employees |
20 |
|
|
| www.bdsinternational.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug delivery technologies with significant outlicenses as well as a proprietary pipeline. |
|
| Management |
| Mark A. Sirgo, Pharm. D., President and Chief Executive Officer; Andrew L. Finn, Pharm.D., Executive Vice President of Product Development; James A. McNulty, CPA, Chief Financial Officer; Charles E. Dadswell, Esq., General Counsel; Albert J. Medwar, M.B.A., Vice President, Marketing |
| |
|
|
|
|
|
|
|
| Keywords |
| drug delivery technologies, healthcare, BEMA technologies, bioral technologies, buprenorphine |
|
|
|
| Description |
|
Biodelivery Sciences International is a specialty pharmaceutical company using its proprietary drug delivery technologies to develop new applications for proven therapeutics. |
|
| Products / Services |
Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer, was launched in October 2009. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB.
The company’s products/formulations also include BEMA Buprenorphine, which is in phase 2 development for moderate to severe pain. It is also pursuing additional products for the prevention of nausea/vomiting and treatment of migraines.
|
|
| Technology / Differentiation |
| BioDelivery Sciences International's drug delivery technologies include both BEMA and Bioral delivery technologies. The company, using these technologies, develops formulations of pharmaceuticals aimed principally in the areas of pain and oncology supportive care. |
|
| Market / Customers |
BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease.
|
|
| Competitors / Substitutes / Alternatives |
Cephalon Inc., ProStrakan., Gilead Sciences, Inc.
|
|
| Strategy |
BDSI is applying its drug delivery technologies to improve the pharmacokinetics and bioavailability of currently-marketed prescription pharmaceutical products, with plans to outlicense select compounds following proof of principle. The company looks to become a fully integrated pharmaceutical company in the longer term with the ability to develop and commercialize its own products in specialty markets.
|
|
| Status |
| In October 2009, BDSI launched its first product, Onsolis (fentanyl buccal soluble film). Results from a Phase 2 study of BEMA Buprenorphine for pain were also completed and positive results announced. The Company also initiated work on two additional BEMA product candidates. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
